Neural Zoomer Plus

found in myasthenia gravis disease

found in myasthenia gravis disease

a compound that is a specific agonist for the AMPA receptor

related to paraneoplastic syndrome (especially Stiff person syndrome) and autoimmune encephalitis

related to paraneoplastic syndrome (especially Stiff person syndrome) and autoimmune encephalitis

Anti-Amyloid Beta (1-42) antibodies (IgG + IgA) measure your immune system’s response against beta-amyloid peptides, the proteins that can accumulate in the brain and contribute to neuroinflammation and neurodegenerative changes. Beta-amyloid is most widely known for its association with Alzheimer’s-type pathology, though it can also increase in response to other neurological stressors. This marker does not diagnose Alzheimer's disease. Instead, it reflects whether your immune system is reacting to amyloid-beta fragments, which may signal inflammation, immune activation, or breakdown in neuronal protein clearance mechanisms. A mild elevation in Anti-Amyloid Beta (1-42) IgG + IgA suggests low-grade immune activation toward amyloid-beta proteins. This may reflect early neuroimmune signaling, mild blood-brain barrier imbalances, or metabolic and inflammatory stress that can affect brain health over time. This does not diagnose Alzheimer’s disease. What this may suggest • Subtle neuroinflammation • Early brain-immune communication shifts • Lifestyle-related inflammatory or metabolic strain Supportive steps • Optimize sleep and stress regulation • Emphasize anti-inflammatory foods and omega-3 fats • Maintain blood sugar stability • Exercise regularly for brain circulation • Address gut-brain inflammation (fiber, probiotics, diverse plants) Re-testing and comprehensive brain health review may be helpful if cognitive symptoms or family history exist.

Anti-Amyloid Beta (25-35) antibodies (IgG + IgA) measure the immune system’s response to a specific fragment of amyloid-beta protein known as Aβ 25-35. This peptide is one of the most neurotoxic amyloid fragments studied in neuroscience research. It can contribute to oxidative stress, mitochondrial dysfunction, neuronal inflammation, and synaptic damage when present in the brain. This test does not diagnose Alzheimer’s disease. Instead, it helps evaluate whether your immune system is reacting to this amyloid fragment, which may reflect neuroinflammation, impaired protein clearance, or blood-brain barrier stress. A mild elevation in Anti-Amyloid Beta (25-35) IgG + IgA suggests early or low-grade immune recognition of a neurotoxic amyloid fragment. This reflects subtle neuroinflammatory signaling or metabolic stress affecting the brain-immune axis. This does not diagnose Alzheimer’s disease. Possible meaning • Mild neuroinflammation or oxidative stress • Early shifts in amyloid immune signaling • Lifestyle-related inflammation or metabolic strain Supportive actions • Improve sleep quality and routine • Follow anti-inflammatory nutrition • Support gut-brain axis and fiber intake • Exercise regularly, reduce stress • Maintain balanced blood sugar levels Retesting and proactive brain-health strategies are reasonable, especially with family history or cognitive symptoms.

Anti-Amyloid Beta (25-35) (IgM) measures early-phase immune activity against a highly reactive fragment of amyloid-beta protein. The 25-35 segment of beta-amyloid is considered one of the most neurotoxic forms, associated with: • Oxidative stress • Mitochondrial dysfunction • Neuronal inflammation and injury • Disruption of synaptic function The IgM antibody response represents the initial immune response—meaning this marker can reflect early or acute immune recognition, rather than the longer-term or chronic activation signaled by IgG or IgA. This marker does not diagnose Alzheimer’s disease. Rather, it may offer insight into early neuroimmune stress and potential vulnerability in brain-immune communication pathways. A mild elevation in Anti-Amyloid Beta (25-35) (IgM) suggests early-stage immune recognition of a neurotoxic amyloid fragment. IgM responses often indicate the initial phase of immune activation, which may precede chronic inflammation. This does not diagnose Alzheimer’s disease. What it may suggest • Early neuroinflammatory signaling • Blood-brain barrier or protein-clearance stress • Lifestyle-related oxidative or metabolic strain Suggested support • Optimize sleep and stress regulation • Anti-inflammatory, high-antioxidant diet • Regular exercise for brain circulation • Improve gut health and fiber intake • Maintain stable blood sugar Monitoring and proactive lifestyle care are beneficial, especially with cognitive symptoms or family history.

serum marker of neuromyelitis optica

serum marker of neuromyelitis optica

The "Anti-Cerebellum" marker is a crucial test component designed to detect autoantibodies targeting the cerebellum, which is a part of the brain responsible for coordinating voluntary movements, including posture, balance, coordination, and speech. The presence of these autoantibodies can indicate an autoimmune response against the cerebellum, potentially leading to neurological disorders such as cerebellar ataxia. This condition is characterized by difficulties in balance, movement, and possibly affecting speech and eye movements, profoundly impacting an individual's quality of life.

Anti-Contactin-associated protein-like 2 (CASPR2) antibodies, including both IgG and IgA classes, are autoantibodies targeting the CASPR2 protein, a component of the voltage-gated potassium channel complex located in the nervous system. The presence of these antibodies is associated with a spectrum of neurological conditions, often termed CASPR2-antibody associated syndromes, which include neuromyotonia (also known as Isaac's syndrome), Morvan syndrome, and autoimmune forms of limbic encephalitis. Patients with anti-CASPR2 antibodies can present with various symptoms depending on the affected region of the nervous system. In neuromyotonia, symptoms may include muscle twitching, cramps, and stiffness, whereas limbic encephalitis is characterized by memory loss, confusion, seizures, and sometimes psychiatric symptoms. Morvan syndrome is distinguished by a combination of neuromyotonia and encephalitis symptoms, along with autonomic dysfunction like sleep disturbances, sweating, and cardiac irregularities. The dual presence of IgG and IgA anti-CASPR2 antibodies can have different pathological implications. IgG antibodies are generally considered to be pathogenic, disrupting ion channels and associated proteins, leading to neuronal hyperexcitability or synaptic dysfunction. The role of IgA antibodies in neurological diseases is less clear but is an active area of research. The combination of both antibody types may suggest a robust or complex autoimmune response and might influence the severity of the disease or response to therapy. Diagnosing CASPR2-associated syndromes often involves the detection of these antibodies in the serum or cerebrospinal fluid (CSF). The detection serves not only for diagnosis but also for indicating a potential paraneoplastic etiology, as these antibodies can be associated with tumors, particularly thymomas. Treatment strategies for conditions associated with anti-CASPR2 antibodies include immunotherapies such as corticosteroids, plasmapheresis, immunoglobulins, and immunosuppressants. In cases where a tumor is present, treatment also involves addressing the neoplasm. Monitoring the levels of anti-CASPR2 antibodies can be part of the management, helping to gauge the effectiveness of these therapies. In summary, the presence of anti-CASPR2 antibodies, both IgG and IgA, is a critical marker for a variety of autoimmune neurological conditions. Their detection helps in diagnosing complex syndromes, suggests possible underlying malignancies, and informs a tailored approach to treatment, which is crucial given the potential for these disorders to be both severe and treatable.

Anti-Contactin-associated protein-like 2 (CASPR2) antibodies of the IgM class are less commonly reported compared to their IgG counterparts but represent an important aspect of the immune response in certain autoimmune neurological disorders. CASPR2 is a cell adhesion molecule that plays a significant role in the proper functioning of the nervous system, particularly in the juxtaparanodal regions of myelinated axons, where it helps to cluster potassium channels. These potassium channels are crucial for maintaining the electrical excitability of nerve cells. When anti-CASPR2 IgM antibodies target this protein, they can disrupt normal neuronal function, leading to a range of clinical manifestations. The presence of IgM antibodies is generally indicative of an acute or recent onset of the immune response. In the context of anti-CASPR2 antibodies, IgM positivity can suggest a newly developed autoimmune reaction, potentially leading to neurological conditions such as limbic encephalitis, characterized by inflammation of the limbic system, or neuromyotonia, which involves muscle stiffness and spasms. Other associated conditions can include Morvan's syndrome, where patients experience a combination of neuromyotonia, autonomic dysfunction, and encephalitic symptoms. Patients with anti-CASPR2 IgM antibodies might present with a variety of symptoms such as seizures, memory issues, sleep disturbances, and autonomic dysfunction, depending on the extent and location of the immune-mediated attack. These clinical features necessitate a comprehensive evaluation to rule out other potential causes and to confirm the autoimmune etiology. The therapeutic approach to conditions associated with anti-CASPR2 IgM antibodies typically involves immunomodulatory treatments aimed at reducing the antibody-mediated immune response. This may include therapies such as corticosteroids, plasma exchange, or intravenous immunoglobulin (IVIG). In some cases, the detection of anti-CASPR2 IgM antibodies can also prompt a search for an underlying malignancy, as paraneoplastic syndromes can sometimes be associated with the presence of these antibodies. While the detection of IgM class antibodies against CASPR2 is less common and less studied than IgG, their presence is still a crucial diagnostic clue and can have significant implications for the management and prognosis of affected individuals. Ongoing research into the role of IgM antibodies in autoimmune neurological disorders continues to shed light on their pathogenic potential and the mechanisms through which they contribute to disease processes.

react with a 66 kd brain protein

react with a 66 kd brain protein

Anti-Dopamine (IgG + IgA) measures the immune system’s activity against dopamine, a key neurotransmitter involved in: • Mood regulation and motivation • Cognition and executive function • Reward and emotional processing • Motor control and coordination • Nervous system stress response The presence of these antibodies suggests the immune system may be reacting to dopamine or dopamine-related structures. This may reflect neuroimmune activation, neurotransmitter dysregulation, or increased permeability in the blood-brain barrier, allowing the immune system to encounter brain-associated molecules. This test does not diagnose a neurological disease. Instead, it acts as an early immune-based marker of possible dopamine pathway stress or autoimmune-associated neuroinflammation. A mild elevation in Anti-Dopamine (IgG + IgA) suggests subtle immune activity toward dopamine-related pathways. This may indicate: • Early-phase neuroimmune signaling • Mild neurotransmitter stress or imbalance • Lifestyle or inflammatory strain affecting dopamine pathways This result does not diagnose a neurological condition. Supportive steps • Improve sleep, stress, and circadian rhythm • Anti-inflammatory diet and omega-3 intake • Regular exercise to support dopamine production • Support gut health and fiber intake • Maintain stable blood sugar • Ensure adequate protein and key nutrients (B6, folate, iron) Helpful to monitor, especially with mood, motivation, or cognitive symptoms.

Anti-Dopamine Receptor 1 (IgG + IgA) – Neural Zoomer Plus (Vibrant America) What is Anti-Dopamine Receptor 1 (IgG + IgA)? The Anti-Dopamine Receptor 1 (D1R) antibodies test measures IgG and IgA antibodies against dopamine receptor 1 (D1R), a key receptor in the brain involved in cognitive function, movement, and motivation. The presence of these antibodies may indicate immune system activity against dopamine receptors, potentially affecting neurological function. Why is this test important? Dopamine receptor dysfunction has been linked to neuropsychiatric and autoimmune conditions, including: Autoimmune encephalitis – A condition where the immune system attacks brain cells, leading to neurological symptoms. Basal ganglia disorders – Such as Sydenham's chorea, where antibodies may disrupt dopamine signaling, causing movement abnormalities. Neuroinflammation & cognitive impairment – Elevated levels may suggest underlying brain inflammation that could contribute to memory issues, anxiety, or depression. What do IgG and IgA mean in this context? IgG antibodies – Suggest chronic or past exposure to an antigen, indicating a longer-term immune response. IgA antibodies – Primarily found in mucosal tissues, suggesting immune activation at the blood-brain barrier or within the nervous system. Interpreting Results Elevated levels may suggest an autoimmune or inflammatory response targeting dopamine receptors, potentially impacting brain function. Low or undetectable levels are generally considered normal and indicate no significant immune response. Next Steps If levels are elevated, further evaluation by a neurologist or functional medicine practitioner may be beneficial. Additional tests for autoimmune encephalitis, PANS/PANDAS, or neuroinflammation could provide deeper insight into potential causes and treatment strategies.

Anti-Dopamine Receptor 2 (IgG + IgA) – Neural Zoomer Plus (Vibrant America) What Is Anti-Dopamine Receptor 2 (IgG + IgA)? The Anti-Dopamine Receptor 2 (DRD2) antibodies test measures immune reactivity to dopamine receptor 2 (DRD2) in the brain. Dopamine receptors play a crucial role in neurotransmission, regulating movement, cognition, mood, and behavior. The presence of IgG and IgA antibodies against DRD2 may indicate an autoimmune reaction targeting these receptors. Why Is This Marker Important? Dysregulation of dopamine receptor 2 is linked to neurological, psychiatric, and autoimmune conditions. Elevated Anti-DRD2 IgG or IgA levels may suggest: Neuroinflammation and autoimmune encephalopathy Basal ganglia dysfunction, potentially associated with movement disorders Neuropsychiatric symptoms, including OCD, tics, and mood disorders PANDAS/PANS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections) Post-infectious autoimmunity, particularly after bacterial or viral infections Understanding IgG and IgA Results Elevated IgG: Suggests a systemic, chronic immune response against DRD2, potentially linked to long-term neuroinflammation. Elevated IgA: May indicate mucosal immune activation, such as gut-brain axis dysfunction or an ongoing autoimmune response. Conditions Associated with Anti-DRD2 Antibodies Autoimmune encephalitis Basal ganglia-related movement disorders (e.g., Parkinson’s-like symptoms, dystonia) Schizophrenia and other psychiatric disorders Obsessive-compulsive disorder (OCD) Tic disorders and Tourette syndrome PANDAS/PANS (post-infectious neuroimmune conditions) Potential Causes of Elevated Anti-DRD2 Antibodies Molecular mimicry (cross-reactivity from infections like streptococcus or viruses) Dysbiosis and leaky gut (gut-brain axis dysfunction) Chronic neuroinflammation Environmental triggers, including toxins or heavy metals What to Do If Your Anti-DRD2 Antibodies Are Elevated If this marker is elevated, further evaluation may be necessary. Potential next steps include: Functional neurology or immunology evaluation Checking for infections (e.g., Streptococcus, Lyme disease, viral triggers) Assessing gut health (intestinal permeability, microbiome imbalances) Addressing neuroinflammation with anti-inflammatory and neuroprotective strategies Considering autoimmune modulation therapies Final Thoughts The presence of Anti-Dopamine Receptor 2 (IgG + IgA) antibodies on the Neural Zoomer Plus panel may indicate an underlying autoimmune or neuroimmune process. Identifying and addressing potential triggers can be key to managing symptoms and restoring neurological balance. If you have concerns about your results, consult a healthcare professional specializing in neuroimmunology or functional medicine.

The "Anti-Endothelin A Receptor" marker plays a critical role in the NeuralZoomer panel. Endothelin A receptor is a protein found on the surface of certain cells within the body and is involved in regulating various functions, including blood pressure and inflammation. When the immune system mistakenly targets and produces antibodies against the endothelin A receptor, it can lead to vascular issues and contribute to the development of autoimmune diseases. Endothelin peptides modulate the development of distinct neural cell types, including Schwann cells, astrocytes, and neural crest cells, as well as physiologic growth and development. The endothelin A receptor has a greater affinity for ET-1, one of the peptides of endothelin. The endothelin A receptor auto-antibodies are found in vascular dementia.

a blood based diagnostic marker of brain injury

a blood based diagnostic marker of brain injury

important cell surface receptor for viral invasion, cancers, and neurological disorders

important cell surface receptor for viral invasion, cancers, and neurological disorders

Anti-glycine receptor (GlyR) antibodies, including IgG and IgA classes, are autoantibodies directed against the glycine receptor, a key inhibitory neurotransmitter receptor in the central nervous system. The presence of these antibodies is most commonly associated with autoimmune disorders such as stiff-person syndrome (SPS) and its variants, including progressive encephalomyelitis with rigidity and myoclonus (PERM). These conditions are characterized by severe muscle stiffness, spasms, and functional impairment due to disrupted inhibitory signaling in the spinal cord and brainstem. The detection of anti-GlyR antibodies, especially of the IgG type, supports the diagnosis of these neurological disorders and can guide immunotherapy treatments. The IgA class of anti-GlyR antibodies may also have clinical relevance, although less is known about their exact role compared to IgG. The measurement of these antibodies is done through specialized laboratory tests, which can be critical for both diagnosis and management of affected individuals.

Anti-glycine receptor (Anti-GlyR) antibodies of the IgM class are a type of autoantibody directed against glycine receptors in the central nervous system. Glycine receptors are crucial for the regulation of motor and sensory pathways due to their inhibitory function in neurotransmission. When IgM antibodies bind to these receptors, they can disrupt normal inhibitory signaling, leading to a range of neurological symptoms. The presence of anti-GlyR IgM is particularly significant because IgM is usually the first antibody class to rise in response to an antigen and can indicate an acute phase of an immune response. While less commonly discussed than IgG anti-GlyR antibodies, which are associated with conditions like stiff-person syndrome (SPS) and PERM (progressive encephalomyelitis with rigidity and myoclonus), IgM antibodies may also be implicated in similar disorders or suggest a different aspect of the immune response. Clinically, patients with elevated anti-GlyR IgM may present with symptoms like muscle stiffness, spasms, cramps, and neuromyotonia. These symptoms arise due to the impaired inhibitory function in neuronal pathways. The detection of anti-GlyR IgM antibodies aids in the diagnosis of these conditions, especially when the clinical presentation is atypical or when other more common antibodies are not present. Furthermore, the presence of IgM antibodies can sometimes indicate a recent infection or another immune-triggering event that has led to the production of these autoantibodies. In some cases, this could also suggest a paraneoplastic origin, where the antibodies are formed in response to a tumor. The treatment for disorders associated with anti-GlyR IgM antibodies often includes immunotherapies such as corticosteroids, plasmapheresis, or intravenous immunoglobulin (IVIG), which aim to reduce the levels of antibodies and alleviate symptoms. The effectiveness of these treatments can sometimes be monitored by measuring changes in the antibody titers, although clinical response remains the primary measure of treatment success. In summary, anti-GlyR IgM antibodies are important in the context of autoimmune neurological disorders, aiding in diagnosis, indicating potential etiologies, and guiding treatment approaches. Their detection underscores the complex nature of autoimmune responses in the nervous system and the need for careful clinical evaluation to manage the associated disorders effectively.

associated with multi-focal motor neuropathy

associated with multi-focal motor neuropathy

potential peripheral nerve antigen for neuropathy-associated autoantibodies

potential peripheral nerve antigen for neuropathy-associated autoantibodies

Herpes simplex virus 1 (HSV-1) is a member of the herpesvirus family, Herpesviridae, that infect humans. HSV-1 (which produces most cold sores) is ubiquitous and contagious. As a neurotropic and neuroinvasive virus, HSV-1 persists in the body by becoming latent and hiding from the immune system in the cell bodies of neurons. HSV-1 has been reported to have a pathogenesis role in Herpes simplex encephalitis (HSE) and seropositivity to HSV-1 antibodies has been correlated with increased risk of Alzheimer's disease.

most frequent manifestation of sensory neuropathy

most frequent manifestation of sensory neuropathy

The "Anti-Hydroxytryptamine" marker is an important indicator used to assess the potential for neurological disorders. Hydroxytryptamine, more commonly known as serotonin, is a crucial neurotransmitter in the human brain, playing a pivotal role in regulating mood, sleep, and digestion, among other vital functions. When the immune system produces antibodies against serotonin, indicated by the "Anti-Hydroxytryptamine" marker, it can signify an abnormal immune response that might affect neurological health. The presence of these antibodies could potentially lead to a variety of neurological conditions, as serotonin's normal function is disrupted, affecting the brain's communication pathways. These autoantibodies are found mainly in autoimmune encephalitis.

Anti-LGI1 (IgG + IgA) measures immune reactivity to LGI1 (leucine-rich glioma-inactivated protein), a protein involved in: • Neuronal signaling and communication • Synaptic function and plasticity • Regulation of cognitive processing and memory • Maintenance of healthy electrical activity in the brain LGI1 plays a key role in how nerve cells communicate and stabilize signaling. The presence of IgG + IgA antibodies suggests the immune system may be reacting to LGI1 or related neural structures, which may reflect neuroinflammation, synaptic stress, or autoimmune-mediated neurological signaling changes. This marker is part of a brain-immune activation screen and does not by itself diagnose autoimmune encephalitis or seizure disorders, but may offer early clues of immune involvement in neurological pathways. A mild elevation in Anti-LGI1 (IgG + IgA) suggests subtle immune recognition of a neural signaling protein. This may reflect early neuroimmune activation, inflammation, or stress affecting brain communication pathways. This result does not diagnose autoimmune encephalitis or neurological disease. What it may suggest • Early immune signaling in neuronal pathways • Mild synaptic or neuroinflammatory stress • Lifestyle-related inflammation or metabolic strain Supportive strategies • Optimize sleep, stress, and circadian rhythm • Anti-inflammatory nutrition and omega-3 intake • Regular exercise for brain oxygenation and signaling • Prioritize gut health and fiber intake • Maintain blood sugar stability • Consider antioxidant-rich foods and lifestyle supports Useful to monitor over time, especially if cognitive or mood-related symptoms are present.

The Anti-Ma (IgG + IgA) biomarker is a diagnostic marker used to detect autoantibodies against Ma antigens, which are proteins found in the brain, particularly in the Purkinje cells of the cerebellum. These antibodies are typically associated with autoimmune responses that target the central nervous system (CNS). The Anti-Ma test, often part of a broader neurological autoantibody panel like Vibrant America’s Neural Zoomer Plus, is crucial for identifying potential paraneoplastic syndromes and other neurological autoimmune disorders. What It Measures The Anti-Ma (IgG + IgA) test detects IgG and IgA antibodies directed against Ma antigens, which are involved in neuronal function. These antibodies can target intracellular or membrane-associated proteins in neurons, particularly those related to the cerebellum and brainstem, and are considered a hallmark of certain paraneoplastic neurological disorders. Clinical Relevance Anti-Ma antibodies are strongly associated with paraneoplastic cerebellar degeneration (PCD) and other autoimmune neurological conditions. These conditions occur when the immune system mistakenly attacks the nervous system, often in response to an underlying malignancy. Anti-Ma (IgG + IgA) testing is particularly relevant for diagnosing the following: Paraneoplastic Cerebellar Degeneration (PCD): This condition is often associated with cancers, particularly ovarian, breast, and small-cell lung cancer. Anti-Ma antibodies are found in a significant percentage of patients with PCD and are commonly linked to cerebellar ataxia, which affects motor coordination and balance. Patients may present with subacute cerebellar ataxia, dysarthria (speech difficulty), and nystagmus (involuntary eye movements). Paraneoplastic Syndromes: These are a group of disorders that occur when the immune system targets healthy tissue, often triggered by the presence of cancer. Anti-Ma antibodies can be present in paraneoplastic neurological syndromes, especially those affecting the cerebellum and brainstem. Neurodegenerative Diseases: Some research suggests that Anti-Ma antibodies may also be present in neurodegenerative diseases, though these cases are less common. The role of Anti-Ma in such conditions is still under investigation. Interpretation of Results Positive Result (IgG/IgA): A positive test for Anti-Ma antibodies suggests an autoimmune attack on the nervous system, particularly in the cerebellum. This is commonly seen in paraneoplastic cerebellar degeneration or other autoimmune conditions affecting the CNS. Further testing, including cancer screening (e.g., CT scans, PET scans), is recommended to rule out an underlying malignancy. If a malignancy is found, treating the cancer often leads to stabilization or improvement of neurological symptoms. Negative Result: A negative result typically indicates that Anti-Ma antibodies are not present, which reduces the likelihood of paraneoplastic cerebellar degeneration but does not exclude other autoimmune or neurodegenerative conditions. However, the absence of Anti-Ma antibodies does not rule out the presence of paraneoplastic syndromes, as other autoantibodies may be involved in different presentations of these disorders. Testing Considerations Panel Context: The Anti-Ma (IgG + IgA) test is typically part of a broader neuroautoantibody panel designed to evaluate various antibodies that may contribute to neurological symptoms such as balance issues, muscle weakness, and cognitive dysfunction. It is often used in conjunction with other biomarkers like Anti-Yo, Anti-Hu, and Anti-Ri, which are also associated with paraneoplastic syndromes. Complementary Tests: Cancer Screening: A positive result for Anti-Ma antibodies may prompt further testing to identify any underlying cancer, especially ovarian, breast, or lung cancer, which are most commonly associated with paraneoplastic cerebellar degeneration. CSF Analysis: For patients with neurological symptoms, cerebrospinal fluid (CSF) analysis can provide additional insight into the presence of autoimmune activity in the CNS. Limitations: The presence of Anti-Ma antibodies is not always indicative of paraneoplastic cerebellar degeneration or malignancy. In some cases, these antibodies may be present in non-cancerous autoimmune conditions or neurodegenerative diseases. False positives can also occur in patients with other autoimmune conditions, so clinical correlation with symptoms is essential for accurate diagnosis. Treatment Implications Immunotherapy: For autoimmune conditions, particularly paraneoplastic cerebellar degeneration, immunosuppressive therapies such as IVIg, steroids, or plasmapheresis may be used to reduce the immune response and alleviate symptoms. Cancer Treatment: If a malignancy is identified, tumor resection or other cancer treatments may help improve neurological symptoms associated with paraneoplastic syndromes. Conclusion Anti-Ma (IgG + IgA) testing is an important tool for diagnosing autoimmune neurological disorders, particularly paraneoplastic cerebellar degeneration. A positive result suggests an autoimmune response against the cerebellum, often triggered by an underlying malignancy. Early detection and treatment are crucial for managing both the neurological symptoms and any associated cancer, making this test a key part of comprehensive neurological care.

Myelin-associated glycoprotein (MAG) is a trans-membrane protein

Myelin-associated glycoprotein (MAG) is a trans-membrane protein

These markers indicate a destruction of the blood brain barrier

These markers indicate a destruction of the blood brain barrier

related to myasthenia gravis disease

related to myasthenia gravis disease

a protein believed to be important in the process of myelination of nerves

a protein believed to be important in the process of myelination of nerves

a glycoprotein associated with the myelination of nerves in the central nervous system

a glycoprotein associated with the myelination of nerves in the central nervous system

the major membrane protein of central nervous system (CNS) myelin sheath

the major membrane protein of central nervous system (CNS) myelin sheath

Neurofascin (NF) is a cell adhesion molecule

Neurofascin (NF) is a cell adhesion molecule

related to optical neuropathies

related to optical neuropathies

Purkinje cells, or Purkinje neurons, are a class of GABAergic neurons located in the cerebellum. Purkinje cells are aligned like dominos stacked one in front of the other. Their large dendritic arbors form nearly two-dimensional layers through which parallel fibers from the deeper-layers pass.

What It Measures The test detects IgG and IgA antibodies targeting Purkinje cells, the primary inhibitory neurons in the cerebellum, responsible for motor coordination and cognitive processing. These antibodies may bind to intracellular or membrane-associated proteins, such as ARHGAP26 (linked to cerebellar ataxia) or Yo antigens (e.g., CDR2/CDR2L in paraneoplastic syndromes). Clinical Relevance Anti-Purkinje cell antibodies are associated with: Paraneoplastic Cerebellar Degeneration (PCD): Strongly linked to underlying cancers (e.g., breast, ovarian, or lung malignancies), with 90-98% of anti-Yo-positive cases having neoplasms. Symptoms include subacute cerebellar ataxia, dysarthria, and diplopia. Autoimmune Cerebellar Ataxia: Non-paraneoplastic cases often target antigens like ARHGAP26 or RGS8, causing inflammatory cerebellar damage. Psychiatric and Neurodevelopmental Disorders: Anti-Purkinje antibodies (IgG) are reported in schizophrenia, bipolar disorder, and ADHD, correlating with acute psychopathology and positive symptoms. May disrupt cerebellar-limbic circuits involved in emotion and cognition. Interpretation of Results Positive Result (IgG/IgA): High titers: Strongly suggest paraneoplastic cerebellar degeneration (PCD) or autoimmune ataxia. Immediate cancer screening (e.g., PET-CT) is critical. Low titers: May occur in psychiatric disorders or non-paraneoplastic autoimmunity; requires clinical correlation. Negative Result: Reduces likelihood of antibody-mediated cerebellar pathology but does not exclude other etiologies. Testing Considerations Methodology: Immunofluorescence on cerebellar tissue detects cytoplasmic/membrane binding patterns. Western blot or protein arrays confirm specific antigens (e.g., ARHGAP26, RGS8). Complementary Tests: CSF analysis: Intrathecal antibody synthesis (e.g., elevated IgG index) supports CNS-specific autoimmunity. Cancer biomarkers: Anti-Yo, anti-Hu, or anti-Ri antibodies refine paraneoplastic risk. Limitations: IgA antibodies are rarely reported in Purkinje cell autoimmunity; IgG dominates most pathologies. Cross-reactivity with natural autoantibodies may yield false positives in psychiatric cohorts. Key Pathogenic Insights Antibody Mechanisms: IgG antibodies (e.g., anti-Yo) are internalized by Purkinje cells, inducing calcium dysregulation and cell death. Complement activation exacerbates neuronal injury in ARHGAP26-associated ataxia. Treatment Implications: Immunotherapy: IVIg, steroids, or plasmapheresis for autoimmune ataxia. Oncological intervention: Tumor removal often stabilizes paraneoplastic symptoms. Conclusion Anti-Purkinje cell (IgG + IgA) testing aids in diagnosing cerebellar autoimmunity, particularly paraneoplastic syndromes. While IgG is the principal isotype linked to cell death and ataxia, IgA's role remains unclear. Results must be contextualized with cancer screening, CSF findings, and neurological symptoms.

The Anti-Purkinje cell (IgM) marker on Vibrant America’s Neural Zoomer Plus panel detects IgM-class autoantibodies targeting Purkinje cells, specialized neurons in the cerebellum that are critical for motor coordination. This test is part of a broader evaluation for neurological autoimmunity, helping identify immune-mediated damage linked to conditions like cerebellar ataxia, paraneoplastic syndromes, or neurodegenerative disorders. Key Details: 1. Clinical Relevance Purkinje cell autoantibodies are associated with cerebellar degeneration, which can manifest as balance issues, gait abnormalities, and speech difficulties. IgM reactivity may indicate an acute or ongoing immune response, differing from IgG antibodies, which often reflect chronic autoimmunity. 2. Test Methodology The Neural Zoomer Plus uses proprietary fluorescent analysis to measure IgM (alongside IgG/IgA) reactivity against Purkinje cell antigens, comparing results to a reference population of 192 healthy individuals. Results are classified as In Control (low reactivity), Moderate, or High Risk, which helps guide clinical interpretation. 3. Contextual Insights While IgG anti-Purkinje antibodies (e.g., anti-Yo) are classically linked to paraneoplastic cerebellar degeneration in cancers like breast or ovarian, IgM detection may suggest broader autoimmune processes or early-stage immune activation. The panel’s inclusion of 48 neurological antigens allows differentiation between Purkinje-specific autoimmunity and cross-reactive responses. This marker aids in personalizing treatment plans, such as immunosuppressive therapies or addressing underlying triggers (e.g., infections, malignancies). Always correlate results with clinical symptoms and additional testing for an accurate diagnosis.

Anti-RAGE Peptide (IgG + IgA) – Neural Zoomer Plus Panel What is Anti-RAGE Peptide? The Anti-RAGE peptide (IgG + IgA) marker measures the presence of antibodies against the Receptor for Advanced Glycation End Products (RAGE) in the blood. This receptor plays a crucial role in inflammation, immune system regulation, and neural function. RAGE is highly expressed in the brain, particularly in neurons, microglia, and endothelial cells of the blood-brain barrier. Why is this Marker Important? Elevated levels of anti-RAGE IgG and IgA antibodies suggest an immune response against RAGE, which may indicate underlying neuroinflammation, autoimmune activity, or neurological dysfunction. Since RAGE is involved in inflammatory signaling, oxidative stress, and the progression of neurodegenerative diseases, its dysregulation has been linked to Alzheimer’s disease, multiple sclerosis, and other neuroinflammatory conditions. Potential Clinical Significance: Neuroinflammation: Chronic immune activation against RAGE may contribute to inflammation in the central nervous system (CNS), potentially exacerbating conditions like autoimmune encephalitis, multiple sclerosis (MS), or chronic neuroinflammatory states. Neurodegenerative Diseases: Anti-RAGE antibodies may be implicated in the progression of Alzheimer’s disease, Parkinson’s disease, or amyotrophic lateral sclerosis (ALS) due to RAGE's role in amyloid-beta aggregation and oxidative stress. Blood-Brain Barrier Dysfunction: RAGE is involved in regulating the permeability of the blood-brain barrier (BBB). Antibody activity against RAGE could indicate disruption of the BBB, increasing susceptibility to toxins, infections, and immune-mediated brain disorders. Metabolic and Autoimmune Links: RAGE interacts with advanced glycation end products (AGEs), which accumulate in conditions like diabetes and metabolic syndrome. Its dysregulation is also seen in systemic autoimmune diseases, including lupus (SLE) and rheumatoid arthritis. What Does an Elevated Result Mean? A high level of IgG anti-RAGE peptide antibodies suggests past or ongoing immune activation against RAGE, often linked to chronic inflammation or neurodegeneration. A high level of IgA anti-RAGE peptide antibodies may indicate mucosal immune activation, suggesting a gut-brain connection in neurological symptoms. Next Steps If Elevated: Consider further neurological and inflammatory testing to assess overall neuroimmune function. Evaluate potential triggers such as chronic infections, autoimmune disorders, metabolic dysregulation, or environmental toxins. Implement anti-inflammatory and neuroprotective strategies, including dietary modifications, gut health support, and targeted antioxidant therapy. Key Takeaway: The Anti-RAGE Peptide (IgG + IgA) marker on the Neural Zoomer Plus panel helps identify potential autoimmune and neuroinflammatory processes affecting the brain. Elevated results may suggest an inflammatory, autoimmune, or degenerative neurological condition, making this marker valuable for individuals experiencing brain fog, cognitive decline, neuroinflammation, or autoimmune symptoms.

associated with retinopathy

associated with retinopathy

a highly specific antineuronal antibody

a highly specific antineuronal antibody

Linked to nervous system stress

Linked to nervous system stress

The marker "Anti-Streptococcal A (IgG)" is a specialized test designed to detect the presence of IgG antibodies against Streptococcus A bacteria in the blood. Streptococcus A is a type of bacteria that can cause various infections, ranging from mild throat infections (like strep throat) to more severe diseases such as rheumatic fever, which can affect the heart, joints, skin, and brain. The presence of IgG antibodies specifically indicates a past or ongoing immune response to this bacterium, suggesting previous exposure or infection.

Anti-Tau (IgG + IgA) measures the immune system’s response to tau protein, a structural protein in neurons that helps stabilize microtubules—the internal “tracks” used for nutrient delivery, cell stability, and healthy nerve communication. When tau proteins become damaged or misfolded, they can form tau tangles, which are associated with: • Neuroinflammation • Neuronal instability and injury • Impaired cellular transport and energy function • Cognitive decline in neurodegenerative conditions This test does not diagnose Alzheimer's disease, frontotemporal dementia, or other tau-related disorders. Rather, it helps identify whether the immune system is reacting to tau proteins, which can signal neuroimmune activation, neuronal stress, or early protective immune surveillance. A mild elevation in Anti-Tau (IgG + IgA) suggests early immune awareness of tau proteins, which may reflect subtle neuroinflammation or neuronal stress. This does not diagnose Alzheimer's or other neurodegenerative diseases. What it may suggest • Early-phase immune signaling around neuronal proteins • Mild oxidative or metabolic stress affecting the brain • Possible blood-brain barrier or tau turnover shifts Supportive steps • Prioritize sleep and stress regulation • Anti-inflammatory, polyphenol-rich diet • Regular aerobic + strength exercise • Maintain blood sugar balance • Support gut-brain health Monitoring and preventive care are reasonable, especially if symptoms or strong family history are present.

The Anti-Titin (IgG + IgA) biomarker, measured in Vibrant Wellness' Neural Zoomer Plus panel, assesses immune reactivity to titin, a giant protein critical for muscle elasticity and contraction. This test helps identify autoimmune responses targeting neuromuscular tissues, which may underlie conditions like myasthenia gravis and thymoma-associated syndromes. What It Measures The test detects IgG and IgA antibodies against titin, a structural protein in skeletal and cardiac muscle. Titin stabilizes sarcomeres during muscle contraction, and autoantibodies against it are often linked to neuromuscular junction dysfunction. Clinical Relevance Anti-Titin antibodies are associated with: Myasthenia Gravis (MG): Found in approximately 30% of generalized MG cases, particularly in patients with thymoma (a tumor of the thymus). Associated with severe disease phenotypes and poorer response to acetylcholinesterase inhibitors. Thymoma Screening: The presence of Anti-Titin antibodies may prompt imaging (e.g., chest CT) to rule out thymic tumors. Late-Onset MG: More common in patients over 50, often without thymoma, but with higher rates of muscle-specific kinase (MuSK) antibodies. Interpretation of Results Positive Result (High/Moderate Reactivity): Suggests autoimmune targeting of muscle proteins. Correlates with myasthenia gravis, thymoma, or other neuromuscular disorders. Requires clinical confirmation (e.g., electromyography, acetylcholine receptor antibody testing). Negative Result: Reduces likelihood of titin-associated autoimmune myasthenia but does not exclude other neuromuscular conditions. Testing Considerations Panel Context: The Neural Zoomer Plus evaluates 48 neurological antigens, including titin, to map autoimmune contributors to symptoms like muscle weakness or fatigue. Complementary Tests: Anti-Acetylcholine Receptor Antibodies: Confirms MG diagnosis. Chest Imaging: For thymoma detection. Limitations: Low titin antibody titers may occur in non-autoimmune conditions (e.g., aging, cardiac disease). Results should be interpreted alongside symptoms and other biomarkers. Conclusion Anti-Titin (IgG + IgA) testing on the Neural Zoomer Plus aids in diagnosing autoimmune neuromuscular disorders, particularly myasthenia gravis with thymoma. While positive results guide targeted interventions (e.g., immunosuppression, thymectomy), clinical correlation remains essential.

a building block protein

a building block protein

Voltage-gated calcium channels (VGCCs) are a group of voltage-gated ion channels found in the membrane of excitable cells such as muscle, glial cells, and neurons. They are key transducers of membrane potential changes into intracellular Ca2+ transients that initiate many physiological events. In neurons, voltage-gated Ca2+ channels initiate synaptic transmission. Anti-voltage-gated calcium channel autoantibodies are responsible for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder of the neuromuscular junction.

The Anti-Voltage Gated Calcium Channels (VGCC) IgM biomarker is a specialized test used to detect antibodies against the voltage-gated calcium channels in the nervous system. These calcium channels play a crucial role in the function of neurons, helping to regulate the flow of calcium ions in and out of nerve cells, which is essential for the proper transmission of electrical signals in the brain and throughout the nervous system. What It Measures: This test specifically measures IgM antibodies directed against these voltage-gated calcium channels. IgM is a type of antibody that typically appears early in immune responses. The presence of Anti-VGCC IgM antibodies can suggest an autoimmune response, where the immune system mistakenly targets these calcium channels, potentially disrupting normal nerve cell function. Clinical Relevance: The presence of Anti-VGCC IgM antibodies has been linked to several neurological conditions, most notably paraneoplastic neurologic syndromes (PNS). In PNS, the immune system targets components of the nervous system in response to an underlying malignancy. These conditions may lead to symptoms such as muscle weakness, vision disturbances, memory issues, or even severe conditions like Lambert-Eaton Myasthenic Syndrome (LEMS), a disorder that impairs communication between nerves and muscles. Symptoms and Conditions Associated: Lambert-Eaton Myasthenic Syndrome (LEMS): A condition where the immune system attacks the voltage-gated calcium channels, causing muscle weakness, particularly in the hips and shoulders. Paraneoplastic Syndromes: These occur in the presence of cancer, where the immune system’s response to the tumor inadvertently damages the nervous system, leading to neurological symptoms. Neurological Disorders: These include various forms of neuropathy, encephalitis, and other brain or nerve-related dysfunctions that may arise from autoimmune attacks on the calcium channels. Interpretation of Results: Positive Test Result: A positive result for Anti-VGCC IgM antibodies could suggest the presence of an autoimmune disorder affecting the nervous system, and further diagnostic evaluation may be necessary to investigate underlying causes, such as cancer or other autoimmune conditions. Negative Test Result: A negative result typically suggests that Anti-VGCC IgM antibodies are not present, which may reduce the likelihood of associated conditions like Lambert-Eaton Myasthenic Syndrome or paraneoplastic syndromes, although clinical correlation is still essential for a full diagnosis. Conclusion: The Anti-VGCC IgM test is a valuable tool for detecting autoimmune responses that impact nerve cell function. By identifying these antibodies, clinicians can better understand the potential causes of unexplained neurological symptoms and guide treatment decisions. Early detection of conditions like Lambert-Eaton Myasthenic Syndrome or paraneoplastic syndromes may lead to more effective management and intervention, improving patient outcomes.

The Anti-Voltage Gated Potassium Channels (VGKC) test, measuring IgG and IgA antibodies, is part of specialized diagnostic panels such as the Neural Zoomer panel by Vibrant America. This test is used to detect antibodies against voltage-gated potassium channels, which are essential proteins located on the surface of neurons. These channels regulate the flow of potassium ions in and out of nerve cells, playing a critical role in the electrical activity that drives neural communication. What It Measures: The Anti-VGKC IgG + IgA test specifically measures two types of antibodies (IgG and IgA) that target the voltage-gated potassium channels. IgG antibodies are the most common type of antibody in the bloodstream and often appear later in immune responses, while IgA antibodies are found in mucosal areas, such as the respiratory and gastrointestinal tracts. The presence of these antibodies can indicate an autoimmune response, where the body's immune system mistakenly attacks its own nerve cells, interfering with normal nervous system function. Clinical Relevance: Elevated levels of Anti-VGKC antibodies are associated with several neurological disorders, including autoimmune encephalitis and other paraneoplastic neurological syndromes. These conditions can result in severe neurological symptoms such as memory loss, mood changes, seizures, and in some cases, muscle weakness. Conditions Associated with Anti-VGKC Antibodies: Autoimmune Encephalitis: This is a condition where the immune system attacks the brain, leading to inflammation that affects cognitive function, behavior, and motor skills. One of the most recognized forms is Anti-NMDA receptor encephalitis, but antibodies against VGKCs have also been implicated in this category of disorders. Paraneoplastic Neurological Syndromes (PNS): PNS occur when cancer triggers an immune response that attacks normal tissues, including the nervous system. Patients with Anti-VGKC antibodies may present with neurological symptoms due to this immune reaction, often linked with underlying malignancies such as small cell lung cancer. Neurological Symptoms: These may include cognitive dysfunction, seizures, movement disorders, and autonomic instability. Patients may also experience psychiatric symptoms like anxiety or depression as a result of the nervous system involvement. Interpretation of Results: Positive Test Result: A positive result for Anti-VGKC IgG + IgA antibodies suggests that the body is producing antibodies against its own potassium channels, which can indicate an autoimmune condition affecting the nervous system. Further diagnostic work-up may be needed to identify the underlying cause, including the potential presence of an autoimmune encephalitis or a paraneoplastic syndrome. Negative Test Result: A negative result means that these antibodies were not detected, which typically reduces the likelihood of autoimmune encephalitis or paraneoplastic neurological syndromes. However, a negative result does not entirely rule out these conditions, and clinical evaluation remains essential. Conclusion: The Anti-VGKC IgG + IgA test is a key tool in diagnosing autoimmune neurological disorders. The detection of these antibodies provides important insights into the potential causes of unexplained neurological symptoms, helping clinicians differentiate between autoimmune conditions and other neurological disorders. Early identification and treatment of conditions associated with Anti-VGKC antibodies can improve patient management, potentially leading to better outcomes by addressing the root cause of the symptoms, such as managing inflammation in autoimmune encephalitis or treating underlying cancers in paraneoplastic syndromes.

The Anti-Voltage Gated Potassium Channels (VGKC) IgM test is a diagnostic assay aimed at detecting IgM antibodies targeting components of the VGKC complex. These channels are essential for regulating potassium ion flow in neurons, contributing to nerve signaling and maintaining the electrical activity of the nervous system. What It Measures This test specifically identifies IgM antibodies directed against VGKC-complex proteins. While IgG antibodies are more commonly associated with autoimmune neurological conditions, the presence of IgM antibodies may indicate an early immune response targeting these channels. The VGKC complex includes proteins such as leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein 2 (CASPR2), which are crucial for synaptic function and neuronal communication. Clinical Relevance Anti-VGKC IgM antibodies are less frequently studied compared to their IgG counterparts, but their detection could still provide insights into autoimmune mechanisms affecting the nervous system. VGKC-complex antibodies have been implicated in conditions such as: Limbic Encephalitis: Characterized by cognitive impairment, seizures, and psychiatric symptoms, often associated with LGI1 antibodies. Neuromyotonia: A peripheral nerve hyperexcitability syndrome linked to CASPR2 antibodies. Morvan Syndrome: A rare disorder featuring neuromyotonia, autonomic dysfunction, and insomnia. Interpretation of Results Positive Test Result: Indicates an autoimmune response targeting VGKC-complex proteins. This may suggest conditions like autoimmune encephalitis or neuromyotonia. However, IgM results should be interpreted cautiously as they are less specific than IgG results. Negative Test Result: Reduces the likelihood of VGKC-complex-related disorders but does not rule out other autoimmune or neurological conditions. Conclusion While the Anti-VGKC IgM test is less commonly utilized than assays for IgG antibodies, it may provide supplementary information in diagnosing autoimmune neurological disorders. Further research is needed to clarify its clinical significance and role in disease mechanisms.

The marker "EBNA1 (IgG)" is a crucial indicator for assessing neurological health and potential autoimmune conditions affecting the nervous system. EBNA1 stands for Epstein-Barr Nuclear Antigen 1, and the IgG designation refers to Immunoglobulin G, a type of antibody. This particular marker is significant because it helps detect past infections with the Epstein-Barr virus (EBV), which is known to be associated with a variety of neurological disorders. EBV is a common virus, and while it often causes mild symptoms or goes unnoticed in many people, its connection to neurological conditions can be significant in a subset of individuals. The presence of IgG antibodies against EBNA1 indicates that a person has been infected with EBV at some point in their life, and their immune system has produced antibodies to fight off the virus. In the context of the NeuralZoomer Plus panel, testing for EBNA1 (IgG) antibodies helps healthcare providers understand whether a past EBV infection might be contributing to neurological symptoms or conditions. This information is valuable for developing a comprehensive picture of a patient's neurological health and tailoring treatment approaches to address any identified autoimmune or viral-related issues.

The CMV EIA Antigen (IgG) marker on the Neural Zoomer Plus panel measures IgG antibodies against Cytomegalovirus, a common herpesvirus that infects most people at some point in their lives. EIA (Enzyme Immunoassay) is the method used to detect IgG levels. The IgG class of antibodies indicates past exposure to CMV and the formation of long-term immune memory. CMV is usually dormant in healthy individuals but can cause neurological issues in some cases—especially in the context of autoimmunity, immune dysfunction, or reactivation.

The Epstein-Barr Virus (EBV) p18 IgG marker is a vital component of the NeuralZoomer Plus panel from Vibrant Wellness, designed to assess neurological health and the risk of autoimmunity. EBV, a widespread herpesvirus, infects most people at some point in their lives, potentially leading to infectious mononucleosis. However, many individuals carry the virus asymptomatically. The p18 IgG marker specifically indicates the body's immune response to EBV, focusing on the production of Immunoglobulin G (IgG) antibodies against the virus's p18 protein—a component of the viral capsid antigen (VCA), essential for the virus's infection and replication processes. The presence of IgG antibodies against EBV's p18 suggests a past or chronic infection, offering significant insights into a patient's immune system status and potential neurological or autoimmune disease risk factors. This testing is crucial, as chronic EBV infection is linked to various neurological conditions and autoimmune diseases. The NeuralZoomer Plus panel facilitates early detection and intervention, providing a personalized approach to prevent and manage neurological health issues. By including the EBV p18 marker, the panel offers a comprehensive view of the body's immune activity against EBV, essential for diagnosing and treating conditions with a potential viral cause.

Epstein-Barr Virus p23 (EBV-p23) IgG – What Your Test Result Means What is Epstein-Barr Virus p23? The Epstein-Barr Virus p23 (EBV-p23) marker detects IgG antibodies targeting a specific early antigen (EA-D) protein of the Epstein-Barr Virus (EBV)—a common herpesvirus that infects over 90% of people worldwide. The p23 protein is part of the early antigen complex, which appears during active viral replication. IgG antibodies to p23 suggest that your immune system recognizes and has responded to this specific EBV protein. What Does an Elevated EBV-p23 IgG Mean? Elevated IgG to EBV-p23 may indicate: A recent or reactivated EBV infection, or Ongoing immune system activation in response to latent virus Since p23 is part of the early antigen complex, reactivity may reflect: Viral reactivation under stress or immune suppression Possible contribution to chronic fatigue, autoimmune activity, or neurological symptoms This is particularly important on panels like Neural Zoomer Plus, which look for infections or immune responses that may affect brain and nerve function. EBV Reactivation and Health Impacts While most people carry EBV in a dormant state, reactivation can occur—sometimes without symptoms, and other times with effects such as: Fatigue or brain fog Chronic inflammation Flare-ups in autoimmune conditions (e.g., lupus, MS) Neurological or psychiatric symptoms (in rare cases) Clinical Relevance of EBV-p23 IgG This marker alone does not diagnose a disease, but a positive or elevated result may be meaningful when: You have symptoms like fatigue, cognitive decline, or autoimmunity Multiple EBV antibodies are elevated (e.g., VCA IgG, EBNA IgG, EA-D IgG) Other infections or neural autoantibodies are also detected Summary EBV-p23 IgG measures your immune system’s response to an early antigen of Epstein-Barr Virus. Elevated levels may reflect recent infection, chronic reactivation, or persistent immune system engagement with EBV. This marker is most useful when interpreted alongside your symptoms and other immune or neurological biomarkers.

The marker "VCA gp125 (IgG)" is an important component of a comprehensive test that aims to detect potential neural autoimmunity, which can affect the nervous system and brain health. "VCA" stands for Viral Capsid Antigen, and "gp125" refers to a specific glycoprotein component of the Epstein-Barr Virus (EBV) that this test targets. The "IgG" in the name signifies Immunoglobulin G, a type of antibody. In the context of this test, the presence of IgG antibodies against the VCA gp125 indicates a past or ongoing immune response to the EBV. The Epstein-Barr Virus is known for its association with various conditions, including but not limited to, mononucleosis, certain cancers, and potentially contributing to autoimmune diseases and neurological conditions. The NeuralZoomer Plus panel, offered by Vibrant Wellness, includes this marker as part of its broader effort to identify autoantibodies that could signal the presence of neurological conditions, aiding healthcare providers in diagnosing and managing potential autoimmune-related neurological disorders. This tool is particularly valuable for identifying silent or subclinical conditions that may otherwise go unnoticed, enabling early intervention strategies to prevent or mitigate long-term health issues related to neural autoimmunity.